Ariyan S, Mitchell M S, Kirkwood J M
Surg Gynecol Obstet. 1984 Mar;158(3):238-42.
Twenty-four patients have been treated by regional isolated perfusion with decarbazine for melanoma of an extremity, with a follow-up period of seven to 72 months. None of these patients had any signs or symptoms of toxicity from the drug. The serum glutamic-oxalacetic transaminase level was elevated by the first postoperative day and returned to normal within the next six days. Fourteen of these 24 patients are free of disease for a follow-up period of 23 to 70 months. Three of the seven patients treated for local or intransit metastases are free of disease for five, 60 and 61 months; a fourth patient had subcutaneous metastases of the trunk develop while remaining disease-free in the perfused extremity for 72 months, and a fifth patient perfused for numerous intransit metastases of a leg had resolution of many of the nodules and remains without new lesions for nine months. Decarbazine is recommended as a safe and valuable drug for the perfusion of extremities with melanoma.
24例肢体黑色素瘤患者接受了用达卡巴嗪进行的区域隔离灌注治疗，随访期为7至72个月。这些患者均无该药物毒性的任何体征或症状。术后第一天血清谷草转氨酶水平升高，在接下来的六天内恢复正常。这24例患者中有14例在23至70个月的随访期内无疾病。接受局部或途中转移治疗的7例患者中有3例在5、60和61个月时无疾病；第四例患者在灌注肢体无疾病72个月时出现躯干皮下转移，第五例因腿部多处途中转移而接受灌注的患者许多结节消退，且9个月无新病灶。推荐达卡巴嗪作为灌注肢体黑色素瘤的一种安全且有价值的药物。
